Raymond James Financial’s aTyr Pharma ATYR Stock Holding History

Raymond James Financial’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10K	Buy	16,801 +200	+1%	+$131	﹤0.01%	5362
2026 Q1	$12.9K	Buy	16,601 +640	+4%	+$540	﹤0.01%	5239
2025 Q4	$12.5K	Buy	15,961 +800	+5%	+$657	﹤0.01%	5120
2025 Q3	$10.9K	Sell	15,161 -9,678	-39%	-$43.9K	﹤0.01%	4933
2025 Q2	$126K	Buy	24,839 +10,989	+79%	+$43.2K	﹤0.01%	4746
2025 Q1	$41.8K	Buy	13,850 +3,156	+30%	+$11.5K	﹤0.01%	4652
2024 Q4	$38.7K	Buy	+10,694	New	+$32.4K	﹤0.01%	4641

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial's ATYR Position: Q2 2026 in Review

Raymond James Financial increased its aTyr Pharma (ATYR) stake by 1.2% in Q2 2026, buying an estimated $131 and bringing the position to 16,801 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #5362.

Raymond James Financial first reported a position in ATYR in Q4 2024 and has held it in 7 quarters since. The position peaked at $126K in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Raymond James Financial held 16,801 shares of aTyr Pharma worth $10K as of Q2 2026.
Raymond James Financial bought 200 aTyr Pharma shares in Q2 2026, an estimated $131.
aTyr Pharma made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5362 holding.
Raymond James Financial first reported a position in aTyr Pharma in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's aTyr Pharma position peaked at $126K in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.